Renaissance Technologies (RenTech)'s CAI Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 449,900 shares of Caris Life Sciences, Inc. (CAI) worth $8.04 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in CAI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 120,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Caris Life Sciences (CAI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Caris Life Sciences (CAI) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +120,000 | Add 36.37% | 449,900 | $17.88 |
| Q4 2025 | +104,800 | Add 46.56% | 329,900 | $26.98 |
| Q3 2025 | +225,100 | New Buy | 225,100 | $30.25 |
Renaissance Technologies (RenTech)'s Caris Life Sciences Investment FAQs
Renaissance Technologies (RenTech) first purchased Caris Life Sciences, Inc. (CAI) in Q3 2025, acquiring 225,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Caris Life Sciences, Inc. (CAI) for 3 quarters since Q3 2025.
Renaissance Technologies (RenTech)'s largest addition to Caris Life Sciences, Inc. (CAI) was in Q3 2025, adding 225,100 shares worth $6.81 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 449,900 shares of Caris Life Sciences, Inc. (CAI), valued at approximately $8.04 M.
As of the Q1 2026 filing, Caris Life Sciences, Inc. (CAI) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Caris Life Sciences, Inc. (CAI) was 449,900 shares, as reported at the end of Q1 2026.